{"entity":{"id":"nct02180711","kind":"trial","name":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of Acalabrutinib, Rituximab, Lenalidomide in hodgkin lymphoma and non-hodgkin lymphoma, run by Acerta Pharma BV, active and no longer recruiting.","summary":"Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT02180711 by Acerta Pharma BV, with 113 participants enrolled, started 2014-12-29 and due to reach its primary completion in 2023-08-25. Interventions recorded: acalabrutinib, rituximab (IV), Lenalidomide. Conditions listed: Non Hodgkin Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02180711","url":"https://clinicaltrials.gov/study/NCT02180711"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["acalabrutinib","rituximab","lenalidomide"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02180711","phase":"1/2","setting":"An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma","sponsor":"Acerta Pharma BV","started":"2014-12-29","startedType":"actual","yearReported":2025,"enrolled":113,"enrolledBasis":"registry","outcomes":[{"endpoint":"Part 2: Investigator Assessed Objective Response Rate (ORR) According to the Lugano Classification for Non-Hodgkin Lymphoma (NHL).","primary":true,"unit":"%","arms":[{"name":"Part 2: Acalabrutinib","n":43,"value":60.5,"note":"95% CI 44.4 to 75.0; Figures from the ClinicalTrials.gov results section (first posted 2025-10-15), not from a publication"},{"name":"Part 2: Acalabrutinib + Rituximab","n":1,"value":0,"note":"95% CI 0 to 97.5"}],"source":"https://clinicaltrials.gov/study/NCT02180711?tab=results"}]},"route":"/trials/nct02180711/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}